674 related articles for article (PubMed ID: 27478817)
21. Intensified Infliximab Induction is Associated with Improved Response and Decreased Colectomy in Steroid-Refractory Paediatric Ulcerative Colitis.
Church PC; Ho S; Sharma A; Tomalty D; Frost K; Muise A; Walters TD; Griffiths AM
J Crohns Colitis; 2019 Aug; 13(8):982-989. PubMed ID: 30715240
[TBL] [Abstract][Full Text] [Related]
22. Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study.
Barberio B; Zingone F; D'Incà R; Rovigo L; Bertani L; Bodini G; Ghisa M; Gubbiotti A; Massimi D; Lorenzon G; Savarino EV
Clin Transl Gastroenterol; 2020 May; 11(5):e00177. PubMed ID: 32677808
[TBL] [Abstract][Full Text] [Related]
23. Oral tacrolimus as maintenance therapy for refractory ulcerative colitis--an analysis of outcomes in two London tertiary centres.
Landy J; Wahed M; Peake ST; Hussein M; Ng SC; Lindsay JO; Hart AL
J Crohns Colitis; 2013 Dec; 7(11):e516-21. PubMed ID: 23623737
[TBL] [Abstract][Full Text] [Related]
24. Short- and long-term efficacy of adalimumab salvage therapy after failure of calcineurin inhibitors in steroid-refractory ulcerative colitis.
Nishio M; Ishii Y; Hashimoto Y; Otake H; Ogashiwa T; Tsuda S; Yasuhara H; Saigusa Y; Kimura H; Maeda S; Kunisaki R
Scand J Gastroenterol; 2018; 53(10-11):1236-1244. PubMed ID: 30353757
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice.
Bálint A; Farkas K; Palatka K; Lakner L; Miheller P; Rácz I; Hegede G; Vincze Á; Horváth G; Szabó A; Nagy F; Szepes Z; Gábor Z; Zsigmond F; Zsóri Á; Juhász M; Csontos Á; Szűcs M; Bor R; Milassin Á; Rutka M; Molnár T
J Crohns Colitis; 2016 Jan; 10(1):26-30. PubMed ID: 26392413
[TBL] [Abstract][Full Text] [Related]
26. Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis.
Taxonera C; Rodríguez C; Bertoletti F; Menchén L; Arribas J; Sierra M; Arias L; Martínez-Montiel P; Juan A; Iglesias E; Algaba A; Manceñido N; Rivero M; Barreiro-de Acosta M; López-Serrano P; Argüelles-Arias F; Gutierrez A; Busquets D; Gisbert JP; Olivares D; Calvo M; Alba C;
Inflamm Bowel Dis; 2017 Aug; 23(8):1394-1402. PubMed ID: 28671873
[TBL] [Abstract][Full Text] [Related]
27. Baseline risk assessment of patients with ulcerative colitis: does initial treatment selection influence outcomes?
Mosli M; Alfaer S; Almalaki T; Albeshry A; Aljehani S; Alshmrani B; Habib Z; Jawa H; Qari Y
Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):80-85. PubMed ID: 30199472
[TBL] [Abstract][Full Text] [Related]
28. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.
Sandborn WJ; Sakuraba A; Wang A; Macaulay D; Reichmann W; Wang S; Chao J; Skup M
Curr Med Res Opin; 2016 Jul; 32(7):1233-41. PubMed ID: 26986449
[TBL] [Abstract][Full Text] [Related]
29. Golimumab for moderately to severely active ulcerative colitis.
Kedia S; Ahuja V; Makharia GK
Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
[TBL] [Abstract][Full Text] [Related]
30. Decreasing trends in hospitalizations during anti-TNF therapy are associated with time to anti-TNF therapy: Results from two referral centres.
Mandel MD; Balint A; Golovics PA; Vegh Z; Mohas A; Szilagyi B; Szabo A; Kurti Z; Kiss LS; Lovasz BD; Gecse KB; Farkas K; Molnar T; Lakatos PL
Dig Liver Dis; 2014 Nov; 46(11):985-90. PubMed ID: 25156871
[TBL] [Abstract][Full Text] [Related]
31. Risk of colectomy in patients with ulcerative colitis under thiopurine treatment.
Cañas-Ventura A; Márquez L; Ricart E; Domènech E; Gisbert JP; García-Sanchez V; Marín-Jiménez I; Rodriguez-Moranta F; Gomollón F; Calvet X; Merino O; Garcia-Planella E; Vázquez-Romero N; Esteve M; Iborra M; Gutiérrez A; Vera M; Andreu M;
J Crohns Colitis; 2014 Oct; 8(10):1287-93. PubMed ID: 24726696
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
Trinder MW; Lawrance IC
J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
[TBL] [Abstract][Full Text] [Related]
33. Adalimumab as a second-line biological therapy in children with refractory ulcerative colitis.
Volonaki E; Mutalib M; Kiparissi F; Shah N; Lindley KJ; Elawad M
Eur J Gastroenterol Hepatol; 2015 Dec; 27(12):1425-8. PubMed ID: 26426835
[TBL] [Abstract][Full Text] [Related]
34. Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study.
Yamamoto T; Shimoyama T; Umegae S; Matsumoto K
Aliment Pharmacol Ther; 2016 Mar; 43(6):705-16. PubMed ID: 26762838
[TBL] [Abstract][Full Text] [Related]
35. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
[TBL] [Abstract][Full Text] [Related]
36. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.
Lindsay JO; Armuzzi A; Gisbert JP; Bokemeyer B; Peyrin-Biroulet L; Nguyen GC; Smyth M; Patel H
Dig Liver Dis; 2017 Oct; 49(10):1086-1091. PubMed ID: 28826571
[TBL] [Abstract][Full Text] [Related]
37. Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis.
Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
Aliment Pharmacol Ther; 2016 May; 43(9):994-1003. PubMed ID: 26991059
[TBL] [Abstract][Full Text] [Related]
38. Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis.
Zhou Z; Dai C; Liu WX
Hepatogastroenterology; 2015; 62(138):309-18. PubMed ID: 25916055
[TBL] [Abstract][Full Text] [Related]
39. Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience.
Pouillon L; Baumann C; Rousseau H; Choukour M; Andrianjafy C; Danese S; Peyrin-Biroulet L
Inflamm Bowel Dis; 2019 Apr; 25(5):945-954. PubMed ID: 30329067
[TBL] [Abstract][Full Text] [Related]
40. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort.
Gies N; Kroeker KI; Wong K; Fedorak RN
Aliment Pharmacol Ther; 2010 Aug; 32(4):522-8. PubMed ID: 20500733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
